J.B. Chemicals & Pharmaceuticals Ltd.

“JB Chemicals is a capital-light branded-generics compounder with a durable India cardiac franchise, near-zero net debt, and steadily improving EBITDA margins now approaching 27%, all underpinned by KKR's operational discipline. These are genuine strengths. The problem is valuation: at 47x trailing earnings and only 2.3% FCF yield, the market has already priced in sustained 14%+ earnings compounding, leaving a 10-year base-case return of roughly 2x (~7-8% CAGR) — inadequate compensation for a business carrying Russia/CIS geopolitical exposure (~20% of revenue), Cilacar franchise concentration, and a PE overhang that creates near-term governance uncertainty. The business deserves a watchlist position; the price does not yet deserve capital allocation.”